BioSpace News Archive

BIOREM Inc. (TSX-V: BRM) (“BIOREM” or “the Company”) announces that due to circumstances created by the Covid-19 pandemic, it will be postponing its reporting of the Company’s audited financial statements, accompanying management’s discussion and analysis, and related CEO and CFO certifications for the year ended December 31, 2019

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the first quarter ended March 31, 2020 and revised upward its full-year 2020 financial guidance for total cystic fibrosis (CF) product revenues.

Hologic, Inc. (Nasdaq: HOLX) announced today that it plans to launch a new Aptima® molecular assay to detect the SARS-CoV-2 virus that will run on its market-leading Panther® system.

Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral therapies targeting integrins for the treatment of serious chronic diseases, today announced that the Morphic executive team is scheduled to make a virtual presentation at the BofA Securities 2020 Health Care Conference at 3:00 p.m. ET on Wednesday, May 13, 2020

GlaxoSmithKline plc announced the US Food and Drug Administration approved the company’s supplemental New Drug Application for Zejula, an oral, once-daily poly polymerase inhibitor, as a monotherapy maintenance treatment for women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy, regardless of biomarker status.

Inovalon (Nasdaq: INOV), a leading provider of cloud-based platforms empowering data-driven healthcare, announced financial results for the first quarter of 2020 and updated guidance for the remainder of 2020.

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that company management will participate in three upcoming virtual investor conferences

The Board of Directors of McKesson Corporation declared a regular dividend of 41 cents per share of common stock.

CONMED Corporation announced financial results for the first quarter ended March 31, 2020.

Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company, announced today it will report financial results for the first quarter 2020 after market close on Monday, May 11, 2020.